Trial Profile
Drug Use-Results Survey of Parsabiv [hemodialysis-related secondary hyperparathyroidism]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2018 Status has been changed to active, no longer recruiting.
- 24 Aug 2018 New trial record